000			03130nam a22005055i 4500
001			978-3-7643-8927-7
003			DE-He213
005			20140220083332.0
007			cr nn 008mamaa
008			110830s2012 sz | s |||| 0|eng d
020			_a9783764389277 _9978-3-7643-8927-7
024	7		_a10.1007/978-3-7643-8927-7 _2doi
050		4	_aRM1-950
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a615 _223
100	1		_aItzstein, Mark. _eeditor.
245	1	0	_aInfluenza Virus Sialidase - A Drug Discovery Target _h[electronic resource] / _cedited by Mark Itzstein.
264		1	_aBasel : _bSpringer Basel, _c2012.
300			_aIX, 178p. 58 illus., 21 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aMilestones in Drug Therapy
505	0		_aInfluenza Virus Virology -- Investigating the interaction between influenza and sialic acid – making and breaking the link -- Enzymology of Influenza Virus Sialidase -- Influenza Virus Sialidase and Structure-Based Drug Design -- The Development of Carbohydrate-based Influenza Virus Sialidase Inhibitors -- The Development of Non-carbohydrate-based Influenza Virus Sialidase Inhibitors -- Clinical Experience with Influenza Virus Sialidase Inhibitors -- Resistance Development to Influenza Virus Sialidase Inhibitors.
520			_aInfluenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge. This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance to these inhibitor drugs complement the topic.
650		0	_aMedicine.
650		0	_aImmunology.
650		0	_aToxicology.
650		0	_aMedical virology.
650		0	_aEmerging infectious diseases.
650	1	4	_aBiomedicine.
650	2	4	_aPharmacology/Toxicology.
650	2	4	_aInfectious Diseases.
650	2	4	_aVirology.
650	2	4	_aImmunology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783764389260
830		0	_aMilestones in Drug Therapy
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-7643-8927-7
912			_aZDB-2-SBL
999			_c103943 _d103943